Literature DB >> 22101410

Effect of pomegranate juice on the pharmacokinetics of nitrendipine in rabbits.

Swathi Voruganti1, Kishore Rapolu, Santoshkumar Tota, Shravan Kumar Yamsani, Madhusudan Rao Yamsani.   

Abstract

Pomegranate juice (PJ) is known to be a potent inhibitor of human cytochrome enzymes. The purpose of this study was to investigate the effect of acute and chronic PJ on the pharmacokinetics of oral nitrendipine (10 mg/kg) in rabbits. Male New Zealand rabbits were pretreated with PJ for 1 week and on the last day, a single dose of nitrendipine was given orally. In another group, both PJ and nitrendipine were co-administered to evaluate the acute effect of PJ on nitrendipine pharmacokinetics. The control group received oral distilled water for 1 week and administered with nitrendipine on the last day. Blood samples were collected at different time points and nitrendipine concentration was estimated by high-performance liquid chromatography. Relative to control, the area under the concentration-time curve and peak plasma concentration of nitrendipine were 2.03- and 2-fold, respectively, greater in the PJ-pretreated group. However, co-administration of PJ had no significant effect on these parameters. Further, there was no significant change in the elimination rate constant and elimination half-life of nitrendipine in both PJ co-administered and pretreated groups in comparison with control. These results suggest that PJ inhibits the intestinal metabolism of nitrendipine without affecting hepatic metabolism in rabbits. Although this potential interaction needs to be explored further, the concomitant use of PJ and nitrendipine should be avoided.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101410     DOI: 10.1007/s13318-011-0075-4

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

1.  Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing.

Authors:  M I Gil; F A Tomás-Barberán; B Hess-Pierce; D M Holcroft; A A Kader
Journal:  J Agric Food Chem       Date:  2000-10       Impact factor: 5.279

2.  Why a pomegranate?

Authors:  P Langley
Journal:  BMJ       Date:  2000-11-04

3.  Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.

Authors:  Gareth E Lim; Timao Li; Harpal S Buttar
Journal:  Exp Clin Cardiol       Date:  2003

4.  Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer.

Authors:  Nam Deuk Kim; Rajendra Mehta; Weiping Yu; Ishak Neeman; Talia Livney; Akiva Amichay; Donald Poirier; Paul Nicholls; Andrew Kirby; Wenguo Jiang; Robert Mansel; Cheppail Ramachandran; Thangaiyan Rabi; Boris Kaplan; Ephraim Lansky
Journal:  Breast Cancer Res Treat       Date:  2002-02       Impact factor: 4.872

5.  Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure.

Authors:  M Aviram; L Dornfeld
Journal:  Atherosclerosis       Date:  2001-09       Impact factor: 5.162

6.  Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats.

Authors:  Muneaki Hidaka; Manabu Okumura; Ken-Ichi Fujita; Tetsuya Ogikubo; Keishi Yamasaki; Tomomi Iwakiri; Nao Setoguchi; Kazuhiko Arimori
Journal:  Drug Metab Dispos       Date:  2005-01-26       Impact factor: 3.922

7.  Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats.

Authors:  Masashi Nagata; Muneaki Hidaka; Hiroshi Sekiya; Yohei Kawano; Keishi Yamasaki; Manabu Okumura; Kazuhiko Arimori
Journal:  Drug Metab Dispos       Date:  2006-11-28       Impact factor: 3.922

Review 8.  Pomegranate juice: a heart-healthy fruit juice.

Authors:  Arpita Basu; Kavitha Penugonda
Journal:  Nutr Rev       Date:  2009-01       Impact factor: 7.110

Review 9.  Interactions between grapefruit juice and cardiovascular drugs.

Authors:  David G Bailey; George K Dresser
Journal:  Am J Cardiovasc Drugs       Date:  2004       Impact factor: 3.571

10.  Influence of some bioflavonoids on the transport of nitrendipine.

Authors:  Kandhagatla Rajnarayana; Allenki Venkatesham; Devarakonda R Krishna
Journal:  Drug Metabol Drug Interact       Date:  2008
View more
  5 in total

1.  Pomegranate juice does not affect the disposition of simvastatin in healthy subjects.

Authors:  Soo-Jin Park; Chang-Woo Yeo; Eon-Jeong Shim; Hyunmi Kim; Kwang-Hyeon Liu; Jae-Gook Shin; Ji-Hong Shon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-27       Impact factor: 2.441

2.  Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-05-15       Impact factor: 2.441

3.  Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits.

Authors:  Swathi Voruganti; Shravan Kumar Yamsani; Madhusudan Rao Yamsani
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-10-05       Impact factor: 2.441

4.  Pomegranate Juice does not Affect the Bioavailability of Cyclosporine in Healthy Thai Volunteers.

Authors:  Wirin Anlamlert; Pakawadee Sermsappasuk
Journal:  Curr Clin Pharmacol       Date:  2020

Review 5.  The Challenge and Importance of Integrating Drug-Nutrient-Genome Interactions in Personalized Cardiovascular Healthcare.

Authors:  Ioannis Stouras; Theodore G Papaioannou; Konstantinos Tsioufis; Aristides G Eliopoulos; Despina Sanoudou
Journal:  J Pers Med       Date:  2022-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.